Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 6/20 | 0.84 |
| ▸ | USP2 | O75604 | 1/20 | 0.84 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL6183133 | 0.98 | INMT (0.83) | INMTUSP2ACHECYP1A2CYP2D6 | |
| Bicarbonate SCHEMBL6184428 | 0.98 | INMT (0.81) | INMTUSP2ACHESMN1; SMN2CYP1A2 | |
| Acetic Acid SCHEMBL1691544 | 0.94 | INMT (0.75) | INMTUSP2SMN1; SMN2CYP1A2CYP2C19 | |
| Acetic Acid SCHEMBL1691547 | 0.94 | INMT (0.75) | INMTUSP2SMN1; SMN2CYP1A2CYP2C19 | |
| Acetic Acid SCHEMBL1691556 | 0.94 | INMT (0.75) | INMTUSP2SMN1; SMN2CYP1A2CYP2C19 | |
| Bicarbonate SCHEMBL31253382 | 0.92 | INMT (0.82) | INMTUSP2ACHE | |
| SCHEMBL17417853 | 0.92 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2 | |
| SCHEMBL16583523 | 0.92 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2 | |
| SCHEMBL3047 | 0.92 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2 | |
| SCHEMBL2734323 | 0.92 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3387032-B1 | BLOCKED 1,8-DIAZABICYCLO[5.4.0]UNDEC-7-ENE BICARBONATE CATALYST FOR AEROSPACE SEALANTS | PRC DESOTO INT INC (US) | 2020-04-01 | — | — | EP | claimed |
| US-9988487-B2 | Blocked 1,8-diazabicyclo[5.4.0]undec-7-ene bicarbonate catalyst for aerospace sealants | PRC-DESOTO INTERNATIONAL, INC. (US) | 2018-06-05 | — | — | US | claimed |
| US-20170166689-A1 | BLOCKED 1,8-DIAZABICYCLO[5.4.0]UNDEC-7-ENE BICARBONATE CATALYST FOR AEROSPACE SEALANTS | PRC-DESOTO INTERNATIONAL, INC. | 2017-06-15 | — | — | US | claimed |
| EP-4695339-A1 | LATENT BASE CATALYST AND COATING COMPOSITION INCLUDING THE SAME | SWIMC LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250333378-A1 | HYDROXYL-CONTAINING THIOL-ALKENE ETHERS AND PROCESS OF MAKING AND USING SAME | US GOV AIR FORCE (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2024238605-A1 | LATENT BASE CATALYST AND COATING COMPOSITION INCLUDING THE SAME | SWIMC LLC (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-3475338-B9 | PREPOLYMERS EXHIBITING RAPID DEVELOPMENT OF PHYSICAL PROPERTIES | PRC DESOTO INT INC (US) | 2022-10-19 | — | — | EP | disclosed |
| EP-3475338-B1 | PREPOLYMERS EXHIBITING RAPID DEVELOPMENT OF PHYSICAL PROPERTIES | PRC DESOTO INT INC (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-108350166-B | Non-chromate corrosion inhibiting polythioether sealants | PRC-迪索托国际公司 | 2020-11-10 | — | — | CN | disclosed |
| EP-3387032-B1 | BLOCKED 1,8-DIAZABICYCLO[5.4.0]UNDEC-7-ENE BICARBONATE CATALYST FOR AEROSPACE SEALANTS | PRC DESOTO INT INC (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3387032-B1 | BLOCKED 1,8-DIAZABICYCLO[5.4.0]UNDEC-7-ENE BICARBONATE CATALYST FOR AEROSPACE SEALANTS | PRC DESOTO INT INC (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2011-12-01 | — | — | US | disclosed |
| US-20050171048-A1 | Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences | ISIS PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-6911540-B2 | 2′ Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| EP-0942000-B1 | 2'-Modified oligonucleotides | ISIS PHARMACEUTICALS INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030036649-A1 | 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | disclosed |
| US-6476205-B1 | 2′ Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| EP-0497875-B1 | 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0942000-A2 | 2'Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5466786-A | Drug delivery | GILEAD SCIENCES (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333378-A1 | HYDROXYL-CONTAINING THIOL-ALKENE ETHERS AND PROCESS OF MAKING AND USING SAME | TMT1A, HTR3D, ALDH1A1 | INMT 906/4885USP2 1194/4885ACHE 3617/4885 |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | PNP, ADAR, NUDT1 | INMT 1272/4885USP2 4574/4885ACHE 3499/4885 |
| US-20030036649-A1 | 2' modified oligonucleotides | DCLRE1B, POLRMT, POLM | INMT 373/4885USP2 1087/4885ACHE 2965/4885 |
| US-20050171048-A1 | Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences | ADAR, POLM, POLRMT | INMT 688/4885USP2 2887/4885ACHE 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.